Product

Cystone

Didymocarpus pedicellata extract + Saxifraga ligulata extract + Rubia cordifolia extract + Cyperus scariosus extract + Achyranthes aspera extract + Onosma bracteatum extract + Vernonia cinerea extract + Hajrul yahood bhasma + Shilajit, purified · Himalaya Drug Company

1 form: tablet. In force in Georgia: 1 of 1 (human register).

Cystone, Tablet

tablet, human medicine

vetman assessment

vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.

Dog Attempted adjunctive use for diagnosed non-obstructive urinary disease or urolithiasis after stone-type assessment, without replacing cause-specific veterinary care

2.5/10

Poor / unconvincing

Cat Attempted adjunctive use for diagnosed non-obstructive urinary disease or urolithiasis after stone-type assessment, without replacing cause-specific veterinary care

2.1/10

Poor / unconvincing

Composition / strength

Didymocarpus pedicellata extract65 mg Saxifraga ligulata extract49 mg Rubia cordifolia extract16 mg Cyperus scariosus extract16 mg Achyranthes aspera extract16 mg Onosma bracteatum extract16 mg Vernonia cinerea extract16 mg Hajrul yahood bhasma16 mg Shilajit, purified13 mg

Formulation Type

Tablet

Administration route

By mouth

Manufacturer

Himalaya Drug Company · India

Registration

Georgia Yes, human

In force until 17 Nov 2026

Human (Ministry of Health, RAMA)

In the register: ცისტონი, აბი #100

№ რ-040446

mis.ge (Ministry of Health register incl. past registrations)

Verified on: 16 Oct 2026

EU Not confirmed

EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026

Verified on: 23 Oct 2026

UK Not confirmed

MHRA Products (UK)

Verified on: 23 Oct 2026

US Not confirmed

Drugs@FDA (openFDA)

Verified on: 23 Oct 2026

Controlled in Georgia

Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.

matsne.gov.ge

Verified on: 16 Oct 2026

Information not fully verified No dog or cat dose, frequency, course duration or stopping rule is established. Do not transfer the current Indian adult-human direction of two tablets twice daily, the different European supplement direction, or scale either by body weight. The exact Georgian 100-tablet composition is recorded, but equivalence to other market presentations is not assumed. Keep species-specific no-dose rows and do not split/crush to invent a veterinary regimen.

Cystone

Forms and doses1 of 1 in force in Georgia

Cystone, Tablet

Cystone

Important safety and use flags

Cystone

Important safety and use flags

All of this shows in vetman as you prescribe

Form	Dose	Frequency	Georgia
Tablet	No label dose in the reference yet	-	Georgia Yes, human In force until 17 Nov 2026 Human (Ministry of Health, RAMA) In the register: ცისტონი, აბი #100 № რ-040446 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Cystone, Tablet tablet, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Attempted adjunctive use for diagnosed non-obstructive urinary disease or urolithiasis after stone-type assessment, without replacing cause-specific veterinary care 2.5/10 Poor / unconvincing vetman assessment Cystone tablet, human medicine Assessed clinical scopeDog · Attempted adjunctive use for diagnosed non-obstructive urinary disease or urolithiasis after stone-type assessment, without replacing cause-specific veterinary care · By mouth Care settingVeterinary-supervised off-label use only; in practice no regimen is recommended because target-animal dose and benefit are unestablished. vetman score 2.5/10 Poor / unconvincing Evidence confidence: Low Georgia: Yes, human · № რ-040446 · Verified on 16 Oct 2026 Off-label use Unconvincing off-label canine urinary adjunct: exact human identity is known, but target-animal dose and outcomes are absent and independent human calcium-oxalate evidence is negative. Regulatory and scientific credibility4.0/10 The exact Georgian 100-tablet composition and active human authorisation are traceable, but this is not a veterinary authorisation or dossier; market presentations and human directions differ, and no dog/cat dose, pharmacokinetics or product-level target-animal study is available. Clinical efficacy1.5/10 No controlled exact-product canine outcome evidence was found. Veterinary consensus uses diagnosis- and stone-type-specific diet, hydration, antimicrobials or removal; an independent human trial found no calcium-oxalate chemistry or stone-burden benefit, so sponsor/open-label claims cannot establish canine efficacy. Safety and tolerability2.5/10 Per-tablet composition is known, but canine dose-ranging, repeated-dose laboratory safety, exposure, interaction and organ/reproductive subgroup data are absent; a multi-herb/mineral human tablet cannot be declared safe by body-weight scaling. Clinical practicality1.5/10 A tablet is physically simple, but no veterinary dose, frequency, course, response threshold or stop rule exists; inability to prescribe reproducibly outweighs dosage-form convenience. Full-course cost-effectiveness- No defensible veterinary regimen or course duration exists; price not assessed. Important safety and use flags Human medicine authorised in Georgia, not a veterinary-authorised product. Both dog and cat assessments are off-label. No exact-product controlled dog/cat outcome study or reproducible veterinary dose was found. Do not transfer or scale adult-human tablet directions. Complete ureteral obstruction is excluded by the manufacturer. Any urethral obstruction is an emergency: do not delay catheterisation/decompression, imaging or referral. Similar urinary signs have different causes. Establish anatomy, obstruction, urinalysis/culture and stone type before treatment; Cystone cannot replace diagnosis. Do not substitute it for therapeutic diet and hydration, indicated culture-guided antimicrobials, minimally invasive/surgical removal, lithotripsy or type-specific prevention. An independent placebo-controlled/open-label human calcium-oxalate study found no significant urine-chemistry or stone-burden benefit; sponsor and rodent studies do not establish veterinary efficacy. No validated dog/cat dose, frequency, course, response threshold or stop rule exists. Do not split or crush tablets merely to invent a body-weight regimen. Target-animal multi-herb/mineral exposure and interaction data are absent. Review renal/hepatic disease, dehydration, electrolyte or urine-pH manipulation, diuretics and other herbal products. Review anticoagulant/antiplatelet therapy, bleeding risk, planned procedures, pregnancy/lactation and juvenile use; lack of reports is not proof of safety. Monitor clinical signs, urine, renal values and imaging according to the diagnosed disease. Stop empiric use and escalate immediately if urine output falls, pain/vomiting worsens or obstruction is suspected. Assessment sources Cystone GE register2026 Cystone current page2026 ACVIM urolith consensus2016 ISCAID urinary guideline2019 Independent Cystone trial2011 CaOx prevention review2025 Veterinary CaOx review2009 Cystone sponsor index2026 Canine struvite outcomes2026 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Attempted adjunctive use for diagnosed non-obstructive urinary disease or urolithiasis after stone-type assessment, without replacing cause-specific veterinary care 2.1/10 Poor / unconvincing vetman assessment Cystone tablet, human medicine Assessed clinical scopeCat · Attempted adjunctive use for diagnosed non-obstructive urinary disease or urolithiasis after stone-type assessment, without replacing cause-specific veterinary care · By mouth Care settingVeterinary-supervised off-label use only; in practice no regimen is recommended because target-animal dose and benefit are unestablished. vetman score 2.1/10 Poor / unconvincing Evidence confidence: Low Georgia: Yes, human · № რ-040446 · Verified on 16 Oct 2026 Off-label use Unconvincing off-label feline urinary adjunct: no feline dose or outcome evidence exists, and empiric use risks delaying cause-specific or emergency obstruction care. Regulatory and scientific credibility4.0/10 The exact Georgian 100-tablet composition and active human authorisation are traceable, but this is not a veterinary authorisation or dossier; market presentations and human directions differ, and no dog/cat dose, pharmacokinetics or product-level target-animal study is available. Clinical efficacy1.0/10 No controlled exact-product feline outcome evidence was found. iCatCare requires cause-specific diagnosis for similar urinary signs and emergency treatment of obstruction; human and rodent evidence cannot establish benefit for feline idiopathic cystitis, infection, struvite, calcium oxalate or obstruction. Safety and tolerability2.0/10 Per-tablet composition is known, but feline exposure and tolerability are unstudied; cats have no validated dose and obstruction may deteriorate rapidly, while multi-herb/mineral interaction, organ-disease and reproductive safety remain unknown. Clinical practicality1.0/10 A tablet can be administered, but no feline dose, course or response rule exists and urgent feline urinary deterioration cannot be safely managed through an empiric oral adjunct. Full-course cost-effectiveness- No defensible veterinary regimen or course duration exists; price not assessed. Important safety and use flags Human medicine authorised in Georgia, not a veterinary-authorised product. Both dog and cat assessments are off-label. No exact-product controlled dog/cat outcome study or reproducible veterinary dose was found. Do not transfer or scale adult-human tablet directions. Complete ureteral obstruction is excluded by the manufacturer. Any urethral obstruction is an emergency: do not delay catheterisation/decompression, imaging or referral. Similar urinary signs have different causes. Establish anatomy, obstruction, urinalysis/culture and stone type before treatment; Cystone cannot replace diagnosis. Do not substitute it for therapeutic diet and hydration, indicated culture-guided antimicrobials, minimally invasive/surgical removal, lithotripsy or type-specific prevention. An independent placebo-controlled/open-label human calcium-oxalate study found no significant urine-chemistry or stone-burden benefit; sponsor and rodent studies do not establish veterinary efficacy. No validated dog/cat dose, frequency, course, response threshold or stop rule exists. Do not split or crush tablets merely to invent a body-weight regimen. Target-animal multi-herb/mineral exposure and interaction data are absent. Review renal/hepatic disease, dehydration, electrolyte or urine-pH manipulation, diuretics and other herbal products. Review anticoagulant/antiplatelet therapy, bleeding risk, planned procedures, pregnancy/lactation and juvenile use; lack of reports is not proof of safety. Monitor clinical signs, urine, renal values and imaging according to the diagnosed disease. Stop empiric use and escalate immediately if urine output falls, pain/vomiting worsens or obstruction is suspected. Assessment sources Cystone GE register2026 Cystone current page2026 ACVIM urolith consensus2016 ISCAID urinary guideline2019 Independent Cystone trial2011 CaOx prevention review2025 Veterinary CaOx review2009 Cystone sponsor index2026 iCatCare feline LUTD 20252025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Didymocarpus pedicellata extract65 mg Saxifraga ligulata extract49 mg Rubia cordifolia extract16 mg Cyperus scariosus extract16 mg Achyranthes aspera extract16 mg Onosma bracteatum extract16 mg Vernonia cinerea extract16 mg Hajrul yahood bhasma16 mg Shilajit, purified13 mg Formulation Type Tablet Administration route By mouth Manufacturer Himalaya Drug Company · India Registration Georgia Yes, human In force until 17 Nov 2026 Human (Ministry of Health, RAMA) In the register: ცისტონი, აბი #100 № რ-040446 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU Not confirmed EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 23 Oct 2026 UK Not confirmed MHRA Products (UK) Verified on: 23 Oct 2026 US Not confirmed Drugs@FDA (openFDA) Verified on: 23 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026 Information not fully verified No dog or cat dose, frequency, course duration or stopping rule is established. Do not transfer the current Indian adult-human direction of two tablets twice daily, the different European supplement direction, or scale either by body weight. The exact Georgian 100-tablet composition is recorded, but equivalence to other market presentations is not assumed. Keep species-specific no-dose rows and do not split/crush to invent a veterinary regimen.